Article in Gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Lucas MotaDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Max ZhuDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.ORCID 0000-0003-3533-7028
John N TomeoDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Melina RecareyDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Nyah PatelDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Leena Pradhan-NabzdykDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Frank W LoGerfoDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Patric LiangDivision of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. pliang1@bidmc.harvard.edu.ORCID 0000-0002-8041-120X
Funding
HARVARD-LONGWOOD RESEARCH TRAINING IN VASCULAR SURGERYT32HL007734 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1993 to 2023
$10.5M
MECHANISMS OF PROSTHETIC ARTERIAL GRAFT FAILURER01HL021796 · NHLBI · NEW ENGLAND DEACONESS HOSPITAL · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1987 to 2020
$9.0M
Genetic Engineering of Vein Bypass Grafts in Vascular and Cardiovascular SurgeryR01HL086741 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BHASIN, MANOJ, FERRAN, CHRISTIANE · 2007 to 2022
$7.4M
Harvard-Longwood Short-Term Research Training in Vascular SurgeryT35HL110843 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHRISTIANE FERRAN, FRANK W LOGERFO · 2013 to 2026
$609k
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) 5T32HL007734U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) 5T35HL110843U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL021796U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL086741
6 · The paper itself
Abstract
Gene therapy using siRNA has become a promising strategy to achieve targeted gene knockdown for treatment of cardiovascular pathologies. However, efficient siRNA transfection often relies on cationic delivery vectors such as synthetic cell-penetrating polymers which are susceptible to interference by negatively charged molecules. Anticoagulants such as heparin, which is negatively charged and widely used in cardiovascular applications, may pose a significant barrier to effective siRNA delivery. We therefore conducted in vitro studies utilizing human smooth muscle and endothelial cells transfected with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The impact of heparin and direct thrombin inhibitors on cell-penetrating polymer siRNA transfection. · full record | OpenQuestion